共 61 条
Effects of Testosterone Supplementation on Depressive Symptoms and Sexual Dysfunction in Hypogonadal Men with the Metabolic Syndrome
被引:98
作者:
Giltay, Erik J.
[1
]
Tishova, Yuliya A.
[2
]
Mskhalaya, George J.
[2
]
Gooren, Louis J. G.
[3
]
Saad, Farid
[4
,5
]
Kalinchenko, Svetlana Y.
[2
]
机构:
[1] Leiden Univ, Med Ctr, Dept Psychiat, NL-2300 RC Leiden, Netherlands
[2] Peoples Friendship Univ Russia, Chair Endocrinol, Fac Med Staff Refresher Training, Moscow, Russia
[3] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Amsterdam, Netherlands
[4] Bayer Schering Pharma, Sci Affairs Mens Healthcare, Berlin, Germany
[5] Gulf Med Univ, Sch Med, Ajman, U Arab Emirates
关键词:
Randomized Trial;
Testosterone Administration;
Metabolic Syndrome;
Depression;
Placebo-controlled;
Sexual Dysfunction;
QUALITY-OF-LIFE;
LATE-ONSET HYPOGONADISM;
OLDER MEN;
DOUBLE-BLIND;
REPLACEMENT THERAPY;
TRANSDERMAL DIHYDROTESTOSTERONE;
BIOAVAILABLE TESTOSTERONE;
ERECTILE DYSFUNCTION;
INTERNATIONAL INDEX;
ANDROGEN DEFICIENCY;
D O I:
10.1111/j.1743-6109.2010.01859.x
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Introduction. Low testosterone levels in men are associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality, and sexual dysfunction. Aim. To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS. Main Outcome Measures. The Beck Depression Inventory (BDI-IA), Aging Males' Symptoms (AMS) scale, and International Index of Erectile Function 5-item (IIEF-5) scale at baseline, 18 and 30 weeks were analysed using multilevel analysis. Methods. In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT00696748), 184 men suffering from both the MetS and hypogonadism were included. They were treated for 30 weeks with either parenteral testosterone undecanoate (TU; 1,000 mg IM TU, at baseline, and after 6 and 18 weeks; Nebido (R)) or placebo injections, 105 (92.9%) men receiving TU and 65 (91.5%) receiving placebo completed the 30-week trial. Results. The 184 men were aged mean 52.1 years old (standard deviation [SD] 9.6; range 35-69), with a mean body mass index of 35.5 kg/m2 (SD 6.7; range 25.1-54.8), and a mean total testosterone level of 8.0 nmol/L (SD 4.0). There were significant improvements in BDI-IA (mean difference vs. placebo after 30 weeks: -2.5 points; 95% confidence interval [CI]: -0.9; -4.1; P = 0.003), AMS (-7.4 points; 95% CI: -4.3; -10.5; P < 0.001), and IIEF-5 (+3.1 points; 95% CI: +1.8; +4.4; P < 0.001). The effects on the BDI-IA, AMS, and IIEF-5 were strongest in men with baseline total testosterone levels < 7.7 mmol/L (i.e., median value). Conclusions. TU administration may improve depressive symptoms, aging male symptoms and sexual dysfunction in hypogonadal men with the MetS. The beneficial effects of testosterone were most evident in men with the lowest baseline total testosterone levels. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, and Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-2582.
引用
收藏
页码:2572 / 2582
页数:11
相关论文